Ibrutinib,Venetoclax
roche,janssen,Abbvie
['cll']
#cll #eha2023 kater. mdr guided i-v, vision trial
3 years post randomisation (only for umrd)
32% umrd
no pfs difference btw continuous ibr and stop-start
40% reinitiated rx. 24m median mrd conversion. 2nd umrd in 47%. 